Rigel Pharmaceuticals, Inc. has just released the following news:

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Click here to read the full article

If you have any questions, or would like to contact Investor Relations, please reply to this email.

To change your subscription preferences, please click here